Auscann Group Holdings Growing flexibility to prescribe cannabinoid medicines for critically ill patient

Growing flexibility to prescribe cannabinoid medicines for critically ill patients: Auscann Group Holdings Ltd (ASX: AC8) stock generated outstanding returns in the last six months over 102.3% (as of July 7th, 2017). The rights have been restored to access cannabinoid medicines via a TGA’s Special Access Scheme Category A. Accordingly, Australian medical practitioners will be able to prescribe cannabinoid medicines to critically ill patients. The Therapeutic Goods Administration (TGA) have two access pathways in enabling Australian medical practitioners to prescribe unregistered cannabinoid medicines – the Authorized Prescriber Scheme (APS) and the Special Access Scheme (SAS) Category B. Both of them need medicinal practitioner to apply for and wait for approval from the TGA prior to being able to prescribe. The group believes that excluding cannabinoid medicines from this pathway was not needed as the cannabinoids have the safety evidence from pre-clinical and clinical studies. On the other side, after delivering an outstanding rally, the shares of Auscann Group have cooled down in the last three months, declining by 37.8% (as of July 7th, 2017). Meanwhile, the shares recovered over 11.2% in the last four weeks (as of July 7th, 2017) and we believe the bullish momentum in the stock would continue in the coming months.


To read the complete report CLICK HERE. To get your free report CLICK HERE







The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s